secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001140361-23-029221
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.02, 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVROBIO completes $87.5M sale of cystinosis gene therapy program to Novartis; cash runway extended to Q4 2024
--------------------------------------------------------------------------------

- Sale closed June 9, 2023 for $87.5M cash; proceeds expected to extend cash runway into Q4 2024.
- AVROBIO retains full rights to HSC gene therapy programs for Gaucher, Hunter, and Pompe diseases.
- Term Loan Facility with Silicon Valley Bank repaid in full and terminated upon closing.
- Interim CEO Ostrowski gets base salary increase to $535K, 55% bonus target, and 70,000 RSUs; retention bonuses approved for Ostrowski and CTO Golipour.
- Unaudited pro forma shows net loss improved to $23.7M for Q1 2023 and $16.8M for FY2022 including gain on asset sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123029221/0001140361-23-029221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000114036123029221/brhc20054252_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-029221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer